Trending...
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Sturtevant's Offers Free Ski and Snowboard Edge-and-Wax Services in Bellevue Oct. 29
- New Book Savvy Not Sabotaged Helps Those Hurt by Betrayal Set Boundaries Without Shutting Others Out
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global urinary incontinence treatment drugs market is estimated to be valued at US$ 4,180.6 million in 2020 and is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027).
Key Trends and Analysis:
The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.
According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.
For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.
Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.
Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400
More on Washingtoner
Key Market Takeaways:
The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Competitive Landscape:
Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400
Market Segmentation:
Related Market Intelligence Reports:
More on Washingtoner
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026
Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Key Trends and Analysis:
The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.
According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.
For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.
Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.
Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400
More on Washingtoner
- AI Needs Guardrails Now: A New Movement Asks People Everywhere to Take the Pledge
- Global Leaders Convene in Seattle to Advance Responsible AI and Cross-Border Ecosystems
- Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
- Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
- AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
Key Market Takeaways:
The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Competitive Landscape:
Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400
Market Segmentation:
- Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type:
- Urge Incontinence
- Stress Incontinence
- Over-flow Incontinence
- Mixed Incontinence
- Other Type
- Global Urinary Incontinence Treatment Drugs Market, By Drug Class:
- Anticholinergic/Antispasmodic Agents
- Skeletal Muscle Relaxants
- Antidepressants
- Alpha Blockers
- Topical Estrogens
- Others
- Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Urinary Incontinence Treatment Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
More on Washingtoner
- Steve Weclew is Appointed by STS Capital Partners as Managing Director
- ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search
- New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026
Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
0 Comments
Latest on Washingtoner
- Spokane: SPD are Searching for a Vehicle in Connection with Fatal Hit and Run
- Are the Cameras in Spokane Flock or ALPRs?
- Tacoma: Statement from Emergency Response Leaders on Proposed Changes to Alternative Response
- Access Control Security Shares 5 Ways Retailers Can Prevent Holiday Theft
- Extreme Lead Program Highlights $27 Real Human Traffic Test for Affiliate and Network Marketers
- Call 311 for Non-Emergency Help in City of Spokane Limits
- Paraguay Expedition Offers a Different View of Human Resilience
- Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
- Datavalet Named One of Quebec's Best Workplaces™ for 2026
- Phinge Corporation Engages Sheridan Ross PC for Certain Intellectual Property Matters
- Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers
- Slotozilla Hosts Exclusive Halloween Casino Bonuses for 2026
- Remcon Equipment Marks 35 Years as a Conveyor Company, With 1,500+ Systems Built
- "BROOKLYN, BROOKLYN, BROOKLYN" children's book and official YouTube channel launch on October 27th
- Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
- Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
- Dynamic Relaunch as AI Predictive Cybersecurity Company Optimized to Prevent Threats Proactively: Cycurion, Inc. (N A S D A Q: CYCU)
- EMBER™ Unveils the Workplace Identity Score™ (WIS™), the First Standard for Measuring Workplace Impact on Workforce Performance & Business Growth
- With Oil Prices Surging…Sky Quarry's Nevada Refinery Is Back in Action — CEO Highlights a Powerful New Growth Chapter for (N A S D A Q: SKYQ)
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year